SLAMF7, a critical receptor for phagocytosis of hematopoietic tumor cells during CD47-SIRP-alpha checkpoint blockage

This is the use of the SLAMF7 receptor for thestratification of patients who could benefit from a treatment blocking theCD47-SIRP-a axis, with the aim of increasing the phagocytosis of tumor cells.Alternative treatment would benefit patients with tumorsnegative for SLAMF7. Research suggests that patients with tumors expressing SLAMF7 would be more likely to respond to SIRPα/CD47 blocking therapy: Jean-Claude Sabourin (514) 340 8503

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More